Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma

Rodríguez-Cid, Jerónimo Rafael; García-Acevedo, Orlando; Benjamin-Contreras, Javier; Bonilla-Molina, D.; Flores-Mariñelarena, Rodrigo Rafael; Martínez-Barrera, Luis Manuel; Alatorre-Alexander, Jorge; Sánchez-Ríos, Carla Paola; Flores-Soto, María del Rosario; Santillán-Doherty, Patricio; Peña-Mirabal, Erika

doi:10.21037/jtd.2019.03.38

Cited by 7 publications

(4 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding is consistent with research that has suggested circulating estrogen, which decreases as females age, and increased expression of estrogen receptor beta (ERβ) may play a role in improved survival of MPM. 23,24,30,31 Studies have shown that increased expression of ERβ is an independent prognostic factor for survival, 23 possibly due to its tumor suppressor properties. 24 In addition to its role in improving survival, ERβ may also serve as a target for future treatment as it might indicate better response to therapies, including chemotherapy.…”

Section: Discussionmentioning

confidence: 99%

“…24 In addition to its role in improving survival, ERβ may also serve as a target for future treatment as it might indicate better response to therapies, including chemotherapy. 30,31 It has been suggested that activation of expression of ERβ may have the potential to reverse biphasic histologies 32 and confer a more epithelioid phenotype. 24 Results of this study should be interpreted within the context of the limitations of the LUCADA dataset.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Gender Differences in Outcomes of Patients With Mesothelioma

Alpert¹,

Gerwen²,

Flores³

et al. 2020

American Journal of Clinical Oncology

View full text Add to dashboard Cite

Background-Mesothelioma is a rare and deadly form of cancer, linked to asbestos exposure. Although the United Kingdom (UK) has banned asbestos, the incidence rate remains high. Previous research has indicated that females have better survival than males, but this has never been examined in the UK.Methods-Pleural mesothelioma cases from 2005-2014 were extracted from the UK Lung Cancer Dataset. Multivariable logistic regression was used to assess the clinical and demographic factors associated with gender. A multivariable Cox-proportional hazards model and propensity matching methods were used to assess gender differences in overall survival, while accounting for potential confounders.Results-There were 8,479 (87.8%) males and 1,765 (17.2%) females included in the analysis. Females were significantly younger, with more epithelial histology than males. Females had significantly better overall survival (HR adj : 0.85, 95% CI: 0.81-0.90). Results remained similar when stratifying by age and performance status, and when limiting to patients with epithelial histology.Conclusions-The study increases knowledge about gender differences in mesothelioma survival and is the first to directly examine this in the UK. It further disentangles effects of age, histology and health status. Increased estrogen may improve survival, and could provide a potential target for future therapies.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Gender Differences in Outcomes of Patients With Mesothelioma

Alpert¹,

Gerwen²,

Flores³

et al. 2020

American Journal of Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…Functional consequences of deregulations in ZEB1, ERβ, SP1, and WT1 zinc-finger transcription factors are well studied in breast cancer, lung cancer, pancreatic cancer, and prostate cancer [ 169 , 170 , 171 , 172 ]. Recently, the upregulation of these genes has been shown in MPM, when compared to matched normal counterparts [ 173 , 174 , 175 , 176 ]. Horio et al showed that siRNA-mediated knockdown of ZEB1 (zinc finger e-box binding homeobox 1) led to the suppression of proliferation, and anchorage-dependent and anchorage-independent clonal growth of MPM cells.…”

Section: Functional Genomics Of Malignant Pleural Mesotheliomamentioning

confidence: 99%

Genomics and Functional Genomics of Malignant Pleural Mesothelioma

Çakıroğlu

Şentürk

2020

IJMS

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the mesothelial cells lining the pleural surface of the chest wall and lung. The etiology of MPM is strongly associated with prior exposure to asbestos fibers, and the median survival rate of the diagnosed patients is approximately one year. Despite the latest advancements in surgical techniques and systemic therapies, currently available treatment modalities of MPM fail to provide long-term survival. The increasing incidence of MPM highlights the need for finding effective treatments. Targeted therapies offer personalized treatments in many cancers. However, targeted therapy in MPM is not recommended by clinical guidelines mainly because of poor target definition. A better understanding of the molecular and cellular mechanisms and the predictors of poor clinical outcomes of MPM is required to identify novel targets and develop precise and effective treatments. Recent advances in the genomics and functional genomics fields have provided groundbreaking insights into the genomic and molecular profiles of MPM and enabled the functional characterization of the genetic alterations. This review provides a comprehensive overview of the relevant literature and highlights the potential of state-of-the-art genomics and functional genomics research to facilitate the development of novel diagnostics and therapeutic modalities in MPM.

show abstract

“…Malignant pleural mesothelioma (MPM) is a rare (prevalence 8–30 cases/million/year) and aggressive neoplasm, originating from the mesothelium lining the pleural surface of the lungs [ 1 ], which has been largely attributed to environmental/occupational exposure to asbestos fibers (83% of cases) [ 2 , 3 ]. However, despite the ban of using asbestos in many countries for over 20 years, the incidence of MPM has failed to decline worldwide, with a total of 250,000 deaths anticipated for the next 30 years [ 4 , 5 ] because of the following reasons: (i) a significant lag between first-time exposure to asbestos and the onset of symptoms in an aging, genetically susceptible population (≥ 30–60 years) [ 6 , 7 ]; (ii) on-going use of asbestos in middle-income and low-income countries [ 8 ]; (iii) presence of other risk factors of MPM’s pathogenesis, including refractory ceramic fibers [ 9 ], hormonal factors [ 10 , 11 ], and some mineral (erionite, fluoro-edenite) or chemical exposures [ 12 – 15 ] such as ionizing radiation [ 16 – 18 ].…”

Section: Epidemiology and Clinic Of Malignant Pleural Mesothelioma (Mpm)mentioning

confidence: 99%

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP

et al. 2022

View full text Add to dashboard Cite

Malignant pleural mesothelioma is a rare and aggressive neoplasm, which has primarily been attributed to the exposure to asbestos fibers (83% of cases); yet, despite a ban of using asbestos in many countries, the incidence of malignant pleural mesothelioma failed to decline worldwide. While little progress has been made in malignant pleural mesothelioma diagnosis, bevacizumab at first, then followed by double immunotherapy (nivolumab plus ipilumumab), were all shown to improve survival in large phase III randomized trials. The morphological analysis of the histological subtyping remains the primary indicator for therapeutic decision making at an advanced disease stage, while a platinum-based chemotherapy regimen combined with pemetrexed, either with or without bevacizumab, is still the main treatment option. Consequently, malignant pleural mesothelioma still represents a significant health concern owing to poor median survival (12–18 months). Given this context, both diagnosis and therapy improvements require better knowledge of the molecular mechanisms underlying malignant pleural mesothelioma’s carcinogenesis and progression. Hence, the Hippo pathway in malignant pleural mesothelioma initiation and progression has recently received increasing attention, as the aberrant expression of its core components may be closely related to patient prognosis. The purpose of this review was to provide a critical analysis of our current knowledge on these topics, the main focus being on the available evidence concerning the role of each Hippo pathway’s member as a promising biomarker, enabling detection of the disease at earlier stages and thus improving prognosis.

show abstract

Expression of estrogen receptor beta (ERβ) and its prognostic value in pleural mesothelioma

Cited by 7 publications

References 56 publications

Gender Differences in Outcomes of Patients With Mesothelioma

Gender Differences in Outcomes of Patients With Mesothelioma

Genomics and Functional Genomics of Malignant Pleural Mesothelioma

Molecular Alterations in Malignant Pleural Mesothelioma: A Hope for Effective Treatment by Targeting YAP

Contact Info

Product

Resources

About